Opinion

Video

Exploring a Recently Approved Therapy for Demodex

An expert ophthalmologist discusses a medication which targets enzymes in the Demodex mite, given over a six-week course. 

This is a video synopsis/summary of an Insights involving Neda Shamie, MD.

There is a recently FDA-approved treatment for Demodex blepharitis called Xdemvy (lotilaner ophthalmic solution 0.25%). Xdemvy targets and paralyzes an enzyme only found in the Demodexmite, effectively eradicating the mite. It is used twice daily for 6 weeks to cover the full life cycle. Over the treatment course, thedrug shows an impressively effective response in not just controlling but eradicating Demodexinfestation. It is a fast, highly effective, and reliable treatment.

In studies and clinical practice, Xdemvy eyedrops have not had significant adverse effects. Most patients find it soothing to the ocular surface with no adverse reactions. About 10% of study patients described a burning sensation upon drop installation. Less than 2% developed chalazion or hordeolum while on treatment. Overallit is very safe, highly effective and welltolerated, with a 6-week, twice-daily course, which supports good compliance. Many patients report completing the full course, motivated to control their disease.

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.

Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
Justin Oldham, MD, MS, an expert on IPF
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
Dr Bonnie Qin
Screenshot of an interview with Ruben Mesa, MD
Justin Oldham, MD, MS, an expert on IPF
Ruben Mesa, MD
Amit Garg, MD, Northwell Health
4 KOLs are featured in this series
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo